Osimertinib (Osi) is widely used as a first-line treatment for non-small cell lung cancer (NSCLC) with EGFR mutations. However, the majority of patients treated with Osi eventually relapse within a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results